Fulcrum stockholders should evaluate whether to hold through the merger to receive the ~$270M cash dividend (estimated) plus 5% equity stub in SLTE, or sell into the likely premium. The $245M PIPE provides a strong validation signal for Slate's pipeline, but SLTE-1009 is still pre-Phase 1 data (mid-2027), the combined entity is a pre-revenue biotech with binary clinical risk. Monitor the S-4 filing for exact dividend amount and exchange ratio.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 17 $3.84entry
- T+1 · 3mo ago +0.78%α +1.46% · $3.87
- T+5 · 3mo ago 0.00%α +1.19% · $3.84
- T+20 · 2mo ago −1.56%α +0.42% · $3.78
- T+60 · 7d ago −3.13%α −0.18% · $3.72
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Fulcrum Therapeutics is being acquired by Slate Medicines in an all-stock reverse merger where pre-merger Fulcrum stockholders will own 5% of the combined company (subject to net cash adjustment) and receive an estimated $270M cash dividend immediately before closing. The combined entity will operate as Slate Medicines (ticker SLTE) and focus on Slate's migraine pipeline, including SLTE-1009, backed by a $245M oversubscribed private placement led by Frazier Life Sciences. For Fulcrum stockholders, this is effectively a liquidation event with a large cash dividend and a small ongoing equity stub in a pre-revenue biotech.
Key Financial Metrics
Key Facts
- Pre-merger Fulcrum stockholders to own 5.0% of combined company (subject to net cash adjustment)
- Fulcrum to pay estimated $270.0M cash dividend to pre-merger stockholders immediately before closing
- Fulcrum contributes ~$20.3M net cash to combined entity
- Slate secured $245M oversubscribed private placement led by Frazier Life Sciences
- Combined company cash runway expected into 2029
- Combined company to trade as SLTE on Nasdaq
- Transaction expected to close in Q4 2026
- Slate's lead asset SLTE-1009 is a clinical-stage anti-PACAP/VIP mAb for migraine prevention
Financial Impact
$270M cash dividend to Fulcrum stockholders (estimated) plus 5% equity stake in combined company valued at implied post-money of ~$5.1B based on $245M PIPE for 4.8%? Not calculable from filing alone. Fulcrum's ~$20.3M net cash contribution.
Risk Factors
- Stockholder approval required from both companies, risk of vote failure
- HSR antitrust waiting period and regulatory clearances needed
- SLTE-1009 is pre-Phase 1 with no clinical data yet, binary pipeline risk
- Fulcrum's 5% stub is tiny and illiquid post-merger
- Dividend amount is an estimate subject to Fulcrum's net cash at closing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345962 |
Track record
23 reports on FULC
5 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +7.71% at T+60 after the Jul 15, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $3.72 Now $3.71 −0.27% settles Nov 18
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.73 Now $3.71 −0.40% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
- Nov 12, 20264d ago 425 Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
- Nov 5, 202612d ago EFFECT Neutral 4/10 Entry $3.68 to $3.70 Now $3.71 +0.82% ▲ +0.54% +0.23% vs SPY
- Nov 3, 202613d ago S-4/A Neutral 5/10 Entry $3.74 to $3.77 Now $3.71 −0.80% ▲ +0.80% −0.85% vs SPY
- Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers